Published in Cancer J on August 09, 2010
A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma | NCT00949702
Safety Study of PLX4032 in Patients With Solid Tumors | NCT00405587
STAT3 Inhibitor for Solid Tumors | NCT00955812
STAT3 DECOY in Head and Neck Cancer | NCT00696176
Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist | NCT00960752
Trial of Dacarbazine With or Without Genasense in Advanced Melanoma (AGENDA) | NCT00518895
NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting) | NCT00142454
Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients | NCT00112229
Autologous Vaccination of Stage 4 Renal Cell Carcinoma Combined With Sunitinib (rcc) | NCT00890110
Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer | NCT00301990
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
mTOR regulates memory CD8 T-cell differentiation. Nature (2009) 10.07
Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol (2006) 6.23
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med (2003) 5.96
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol (2010) 5.91
Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol (2004) 5.78
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A (2003) 5.49
Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol (2009) 5.33
Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res (2009) 5.10
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer (2006) 4.93
The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity (2008) 4.44
Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol (2006) 4.23
Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol (2004) 4.09
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A (2008) 3.80
The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med (2006) 3.47
The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res (2009) 3.18
Survival differences between patients with scalp or neck melanoma and those with melanoma of other sites in the Surveillance, Epidemiology, and End Results (SEER) program. Arch Dermatol (2008) 3.11
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer (2010) 3.03
Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J Exp Med (2002) 2.96
Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res (2008) 2.84
The MAPK pathway in melanoma. Curr Opin Oncol (2008) 2.80
The receptor S1P1 overrides regulatory T cell-mediated immune suppression through Akt-mTOR. Nat Immunol (2009) 2.73
Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol (2009) 2.53
Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells. Blood (2008) 2.53
Improving melanoma classification by integrating genetic and morphologic features. PLoS Med (2008) 2.52
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res (2009) 2.32
Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol (2010) 2.20
Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res (2010) 2.20
Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood (2008) 2.09
An essential role for Akt1 in dendritic cell function and tumor immunotherapy. Nat Biotechnol (2006) 2.04
Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol (2008) 2.00
Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res (2000) 1.96
Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol (2006) 1.83
Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res (2009) 1.81
Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J Invest Dermatol (2008) 1.71
Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin. PLoS One (2009) 1.69
Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin Cancer Res (2006) 1.60
A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol (2007) 1.49
Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy. Cancer Res (2009) 1.46
Toll-like receptors and immune regulation: implications for cancer therapy. Oncogene (2008) 1.46
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother (2008) 1.39
mTOR: taking cues from the immune microenvironment. Immunology (2009) 1.38
Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression. Mol Cancer Res (2006) 1.34
Cutaneous melanoma: available therapy for metastatic disease. Dermatol Ther (2006) 1.32
Immunity to melanoma antigens: from self-tolerance to immunotherapy. Adv Immunol (2006) 1.31
Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases. Clin Cancer Res (2009) 1.30
Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in ret transgenic mice spontaneously developing melanoma. Clin Cancer Res (2009) 1.28
Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics. J Immunol (2008) 1.25
Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. Clin Cancer Res (2009) 1.25
Synergy between tumor immunotherapy and antiangiogenic therapy. Blood (2003) 1.23
Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin. J Transl Med (2005) 1.22
Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help. Eur J Pharmacol (2007) 1.21
Bcl-2 overexpression enhances tumor-specific T-cell survival. Cancer Res (2005) 1.19
Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2. Cancer Res (2008) 1.16
IFN-beta pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis. J Immunol (2002) 1.15
Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol (2009) 1.15
The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications. Semin Oncol (2007) 1.14
Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis. J Cutan Pathol (2009) 1.12
Small molecules and targeted therapies in distant metastatic disease. Ann Oncol (2009) 1.08
Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity. J Immunol (2003) 1.08
A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunol Immunother (2008) 1.06
Curcumin induces proapoptotic effects against human melanoma cells and modulates the cellular response to immunotherapeutic cytokines. Mol Cancer Ther (2009) 1.04
Targeting AKT signaling sensitizes cancer to cellular immunotherapy. Cancer Res (2008) 1.01
MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib. Mol Cancer Ther (2009) 1.00
Radiosensitization of melanoma cells through combined inhibition of protein regulators of cell survival. Apoptosis (2008) 0.99
The role of Bcl-2 family members in the progression of cutaneous melanoma. Clin Exp Metastasis (2003) 0.99
Treatment combinations targeting apoptosis to improve immunotherapy of melanoma. Cancer Immunol Immunother (2009) 0.97
Oral DNA vaccines target the tumor vasculature and microenvironment and suppress tumor growth and metastasis. Immunol Rev (2008) 0.95
Recent advances and hurdles in melanoma immunotherapy. Pigment Cell Melanoma Res (2009) 0.95
Progress and controversies in developing cancer vaccines. J Transl Med (2005) 0.93
Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma. Br J Dermatol (2008) 0.92
Tumour-mediated disruption of dendritic cell function: inhibiting the MEK1/2-p44/42 axis restores IL-12 production and Th1-generation. Int J Cancer (2008) 0.92
Apoptosis and melanoma: how new insights are effecting the development of new therapies for melanoma. Curr Opin Oncol (2006) 0.88
Apoptosis of CD4(+)CD25(high) T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2. Cancer Immunol Immunother (2008) 0.87
The vascular phenotype of melanoma metastasis. Clin Exp Metastasis (2003) 0.87
Immunosensitization with a Bcl-2 small molecule inhibitor. Cancer Immunol Immunother (2008) 0.86
Enhanced suppression of melanoma tumor growth and metastasis by combined therapy with anti-VEGF receptor and anti-TYRP-1/gp75 monoclonal antibodies. Anticancer Res (2008) 0.84
Immunotherapy as part of a multidisciplinary approach to melanoma treatment. Front Biosci (2006) 0.84
Interferon-alpha treatment may negatively influence disease progression in melanoma patients by hyperactivation of STAT3 protein. Eur J Cancer (2009) 0.83
Advances in drug development. BRAF validation in melanoma. Clin Adv Hematol Oncol (2010) 0.82
Administration of IFN-alpha enhances the efficacy of a granulocyte macrophage colony stimulating factor-secreting tumor cell vaccine. Cancer Res (2005) 0.82
Enhancement of human melanoma antigen expression by IFN-beta. J Immunol (2007) 0.82
Anti-CTLA4 Antibody Clinical Trials in Melanoma. Update Cancer Ther (2007) 0.81
Experimental therapy using interferon-gamma and anti-Fas antibody against oral malignant melanoma cells. Melanoma Res (2005) 0.80
Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma. Biochem Pharmacol (2010) 0.80
STAT3 as a biomarker of progression in atypical nevi of patients with melanoma: dose-response effects of systemic IFNalpha therapy. J Invest Dermatol (2008) 0.79
Immunomodulatory and anticancer effects of intra-tumoral co-delivery of synthetic lipid A adjuvant and STAT3 inhibitor, JSI-124. Immunopharmacol Immunotoxicol (2009) 0.78
[Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis]. Zhonghua Zhong Liu Za Zhi (2006) 0.76
Tumor evasion may occur via expression of regulatory molecules: a case for CTLA-4 in melanoma. J Invest Dermatol (2008) 0.76
Enhancement of DNA cancer vaccine efficacy by combination with anti-angiogenesis in regression of established subcutaneous B16 melanoma. Oncol Rep (2009) 0.76
Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science (2002) 4.02
Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res (2012) 2.48
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res (2011) 2.44
Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. Clin Trials (2010) 2.24
Patients with Merkel cell carcinoma tumors < or = 1.0 cm in diameter are unlikely to harbor regional lymph node metastasis. J Clin Oncol (2009) 1.94
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
Impact of patient distance to radiation therapy on mastectomy use in early-stage breast cancer patients. J Clin Oncol (2005) 1.75
Sentinel node biopsy in vulvar and vaginal melanoma: presentation of six cases and a literature review. Ann Surg Oncol (2002) 1.50
Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials. Clin Trials (2011) 1.43
CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease. Cancer Res (2004) 1.43
Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups. Clin Cancer Res (2011) 1.42
Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling. J Biol Chem (2004) 1.39
Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic function. J Transl Med (2011) 1.31
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31
A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer. J Immunother (2008) 1.25
Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma. J Immunol (2005) 1.23
Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin. J Transl Med (2005) 1.22
Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2. Cancer Res (2008) 1.16
Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis. J Cutan Pathol (2009) 1.12
Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma. Clin Cancer Res (2011) 1.10
Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma. J Immunother (2010) 1.10
Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptide. Cancer Immunol Immunother (2013) 1.03
Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1R. Melanoma Res (2011) 1.03
Genomic organization, incidence, and localization of the SPAN-x family of cancer-testis antigens in melanoma tumors and cell lines. Clin Cancer Res (2004) 1.01
Use of selected reaction monitoring mass spectrometry for the detection of specific MHC class I peptide antigens on A3 supertype family members. Cancer Immunol Immunother (2004) 1.01
Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47). Clin Cancer Res (2013) 1.00
Surgical management of the patient with metastatic melanoma to the heart. J Card Surg (2013) 0.97
Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis. J Transl Med (2010) 0.97
The vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptides. J Immunother (2012) 0.96
MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma. Clin Cancer Res (2003) 0.96
Subclassification of desmoplastic melanoma: pure and mixed variants have significantly different capacities for lymph node metastasis. J Cutan Pathol (2009) 0.95
Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2. J Immunother (2005) 0.95
Preventing the spontaneous modification of an HLA-A2-restricted peptide at an N-terminal glutamine or an internal cysteine residue enhances peptide antigenicity. J Immunother (2004) 0.94
Intraoperative imaging guidance for sentinel node biopsy in melanoma using a mobile gamma camera. Ann Surg (2011) 0.94
Amelanotic melanomas presenting as red skin lesions: a diagnostic challenge with potentially lethal consequences. Int J Dermatol (2012) 0.93
Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells. J Biol Chem (2006) 0.93
Problems in the interpretation of apparent "radial growth phase" malignant melanomas that metastasize. J Cutan Pathol (2002) 0.93
T cells in the human metastatic melanoma microenvironment express site-specific homing receptors and retention integrins. Int J Cancer (2014) 0.93
Immunotherapy for melanoma. Cancer Control (2002) 0.91
Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies. Vaccine (2009) 0.88
Apoptosis of CD4(+)CD25(high) T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2. Cancer Immunol Immunother (2008) 0.87
Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine. Cancer Immunol Immunother (2014) 0.86
Identification of novel and widely expressed cancer/testis gene isoforms that elicit spontaneous cytotoxic T-lymphocyte reactivity to melanoma. Cancer Res (2004) 0.85
Competition among peptides in melanoma vaccines for binding to MHC molecules. J Immunother (2004) 0.85
Extensive neurocristic hamartoma with skeletal muscle involvement. J Cutan Pathol (2007) 0.85
Evaluation of molecular markers of mesenchymal phenotype in melanoma. Melanoma Res (2010) 0.84
Infrared thermography of cutaneous melanoma metastases. J Surg Res (2012) 0.83
VEGFR-2 expression in human melanoma: revised assessment. Int J Cancer (2011) 0.83
MicroRNAs induced in melanoma treated with combination targeted therapy of Temsirolimus and Bevacizumab. J Transl Med (2013) 0.83
The use of gamma-irradiation and ultraviolet-irradiation in the preparation of human melanoma cells for use in autologous whole-cell vaccines. BMC Cancer (2008) 0.83
Outcome of sentinel lymph node biopsy and prognostic implications of regression in thin malignant melanoma. Melanoma Res (2012) 0.82
Neonatal congenital malignant melanoma with lymph node metastasis. J Clin Oncol (2009) 0.82
Melanoma NOS1 expression promotes dysfunctional IFN signaling. J Clin Invest (2014) 0.81
Identification of a shared epitope recognized by melanoma-specific, HLA-A3-restricted cytotoxic T lymphocytes. Immunol Lett (2003) 0.81
Skin mapping with punch biopsies for defining margins in melanoma: when you don't know how far to go. Ann Surg Oncol (2008) 0.80
Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. J Clin Invest (2016) 0.80
The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopes. J Immunother (2008) 0.79
Research incentive program for clinical surgical faculty associated with increases in research productivity. J Thorac Cardiovasc Surg (2012) 0.78
Utility of sentinel lymph node biopsy for solitary dermal melanomas. J Surg Oncol (2015) 0.78
Assessment of the toxicities of systemic low-dose interleukin-2 administered in conjunction with a melanoma peptide vaccine. J Immunother (2004) 0.78
Two patients with Hailey-Hailey disease, multiple primary melanomas, and other cancers. Arch Dermatol (2011) 0.77
Surgical resection for bulky or recurrent axillary metastatic melanoma. J Surg Oncol (2011) 0.76
Immunolabeling for p16, WT1, and Fli-1 in the assignment of growth phase for cutaneous melanomas. Am J Dermatopathol (2014) 0.76
Lymphoscintigraphy and sentinel node biopsy accurately stage melanoma in patients presenting after wide local excision. Ann Surg Oncol (2003) 0.75
Regional control and morbidity after superficial groin dissection in melanoma. Ann Surg Oncol (2010) 0.75
Long-term outcomes of helper peptide vaccination for metastatic melanoma. Ann Surg (2015) 0.75
Usefulness of prestudy assessment of patient willingness to undergo tissue biopsy for correlative studies in a melanoma vaccine trial. Clin Trials (2012) 0.75
Design, development, and evaluation of a novel retraction device for gallbladder extraction during laparoscopic cholecystectomy. J Gastrointest Surg (2013) 0.75
Inflammatory adverse events are associated with disease-free survival after vaccine therapy among patients with melanoma. Ann Surg Oncol (2014) 0.75
Localization of the Sentinel Lymph Node in Melanoma Without Blue Dye. Ann Surg (2016) 0.75
A triangular intermuscular space sentinel node in melanoma: association with axillary lymphatic drainage. Ann Surg Oncol (2010) 0.75
Short length of stay and rapid recovery to normal function after surgery for metastatic melanoma to abdominal and retroperitoneal viscera. J Surg Oncol (2009) 0.75
A case of spontaneous systemic immunity to melanoma associated with cure after amputation for extensive regional recurrence. Cancer Immunol Immunother (2013) 0.75
Resident research forums stimulate novel research within general surgical training programs. J Surg Educ (2009) 0.75
Histopathologic review of negative sentinel lymph node biopsies in thin melanomas: an argument for the routine use of immunohistochemistry. Melanoma Res (2017) 0.75
Innovations and challenges in melanoma: summary statement from the first Cambridge conference. Clin Cancer Res (2006) 0.75
The heterogeneity of tumor-infiltrating CD8+ T cells in metastatic melanoma distorts their quantification: how to manage heterogeneity? Melanoma Res (2017) 0.75
Low-dose IL-2 induces cytokine cascade, eosinophilia, and a transient Th2 shift in melanoma patients. Cancer Immunol Immunother (2005) 0.75